-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca Acquires Omniose to Boost Vaccine Platform

MT Newswires·11/10/2026 10:01:14
Listen to the news
10:01 AM EST, 11/10/2026 (MT Newswires) -- AstraZeneca (AZN.L, ZN.ST) acquired US-based preclinical biotechnology company Omniose, following a three-year exclusive research collaboration. The transaction strengthens the British drugmaker's vaccine portfolio through Omniose's proprietary bioconjugation platform for conjugate vaccine development, according to a Tuesday release from the acquired company. Omniose will be integrated as a subsidiary under AstraZeneca's Infectious Disease Unit.